Put Options

7 transactions
Quarter Operation Price Per put puts change puts Held SEC Form
Q3 2022

Nov 14, 2022

SELL
$6.66 - $12.39 $18,648 - $34,692
-2,800 Reduced 71.79%
1,100 $8,000
Q2 2022

Aug 15, 2022

BUY
$8.95 - $12.8 $25,059 - $35,840
2,800 Added 254.55%
3,900 $39,000
Q1 2022

May 16, 2022

SELL
$10.05 - $22.48 $502,500 - $1.12 Million
-50,000 Reduced 97.85%
1,100 $14,000
Q4 2021

Feb 14, 2022

SELL
$17.78 - $33.08 $312,928 - $582,208
-17,600 Reduced 25.62%
51,100 $1.17 Million
Q3 2021

Nov 15, 2021

BUY
$10.93 - $23.55 $641,591 - $1.38 Million
58,700 Added 587.0%
68,700 $1.52 Million
Q3 2020

Nov 16, 2020

BUY
$13.19 - $16.66 $54,079 - $68,306
4,100 Added 69.49%
10,000 $147,000
Q2 2020

Aug 14, 2020

BUY
$14.12 - $18.33 $83,308 - $108,146
5,900 New
5,900 $96,000

Others Institutions Holding AUPH

About Aurinia Pharmaceuticals Inc.


  • Ticker AUPH
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 141,892,000
  • Market Cap $1.15B
  • Description
  • Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States and internationally. The company offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license...
More about AUPH
Track This Portfolio

Track Css LLC Portfolio

Follow Css LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Css LLC, based on Form 13F filings with the SEC.

News

Stay updated on Css LLC with notifications on news.